Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

This study assessed the safety, efficacy, pharmacokinetics and immunogenicity of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in patients with metastatic colorectal cancer (mCRC). Patients with untreated mCRC received BI 695502 and chemotherapy (oxaliplatin, leucovorin and 5-fluorour...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Colorectal cancer 2022-11
Hauptverfasser:	Bekaii-Saab, Tanios S, Balser, Sigrid, Lohmann, Ragna, Daoud, Hasan, Liedert, Bernd, Schliephake, Dorothee
Format:	Artikel
Sprache:	eng
Schlagworte:	bevacizumab biosimilar pharmaceuticals colorectal neoplasms patient safety treatment outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!